Anteris Technologies Global Corp.
Close on Oct 19, 2026
- Market cap
- $601.56M
- P/E (TTM)
- –
- Dividend yield
- –
About Anteris Technologies Global
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Anteris Technologies Global Corp. is a structural heart company that develops medical devices to treat aortic stenosis. Its primary product candidate is the DurAVR Transcatheter Heart Valve System, a balloon-expandable transcatheter aortic valve replacement made with a single piece of bioengineered bovine pericardial tissue. The system incorporates the company's proprietary ADAPT anti-calcification tissue technology and is deployed using its ComASUR Delivery System. The technology serves patients suffering from aortic stenosis, including those undergoing initial valve replacement as well as valve-in-valve procedures.
The company operates internationally and conducts clinical trials across North America and Europe, including Denmark and the United States. Its tissue technology has been distributed for use in more than 55,000 patients globally, and over 130 patients have received implants of its transcatheter heart valve worldwide. Anteris Technologies Global Corp. maintains its principal executive offices in Toowong, Queensland, Australia.
Summary of the business section of Anteris Technologies Global's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Anteris Technologies Global Corp.
- Headquarters
- Eagan, MN
- Address
- 860 Blue Gentian Road, Suite 340 55121
- Phone
- (651) 493-0606
- Employees
- 174, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG, Brisbane, Australia
Stock & identifiers
- Ticker
- AVR
- Exchange
- Nasdaq
- IPO date
- Dec 13, 2024
- Shares outstanding
- 97M, Aug 10, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2011514
- CUSIP
- 03675P102
- ISIN
- US03675P1021
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Denis David St | Chief Operating Officer, Director | 161,082 |
| Wayne Paterson | Chief Executive Officer, Director | 203,061 |
| Brent Moen | Chief Financial Officer | – |
| Matthew McDonnell | Chief Financial Officer | 50,183 |
| David B. Roberts | Director | 17,580 |
| Gregory S. Moss | Director | 17,580 |
| Susan Elizabeth Knight | Director | 11,000 |
| Stephen Denaro | Director | 23,722 |
| John D. Seaberg | Director | 47,487 |
| Wenyi Gu | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 174 full time equivalent employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 10, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |